Pallimed Solutions Recalls Dexamethasone PF Due to Sterility Concerns
Pallimed Solutions is recalling Dexamethasone PF compounded in Woburn, MA, due to FDA inspectional findings regarding quality control and sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric for significant health risks such as sterility failures in compounded drugs.
Plain-English summary
Pallimed Solutions Pharmacy in Woburn, Massachusetts, is recalling Dexamethasone PF. The recall covers all lots within their expiry dates and was distributed nationwide.
The recall was initiated following FDA inspectional findings that raised concerns about quality control procedures. These findings specifically impacted the assurance of sterility for the compounded product.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on disposal or replacement.
The recalled product
- Product
- Dexamethasone PF, compounded by Pallimed Solutions Pharmacy, Woburn, MA
- Manufacturer
- Pallimed Solutions
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 25 recalled by Pallimed Solutions under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 25 products in this recall →Related recalls
Same manufacturer · Pallimed Solutions
See all →- SeverePallimed Solutions Recalls Atropine Injection Due to Sterility Concerns
FDA (Drugs) · 2013-08-21
- SeverePallimed Solutions Recalls Trimix Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-08-21
- SevereQuadmix Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-08-21
- SeverePallimed Acetylcysteine Ophthalmic Solution Recalled for Sterility Concerns
FDA (Drugs) · 2013-08-21
- SeverePallimed Solutions Recalls Testosterone Injection Due to Sterility Concerns
FDA (Drugs) · 2013-08-21
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SeverePharmedium Recalls Dexamethasone Sodium Phosphate Due to Sterility Assurance Issues
FDA (Drugs) · 2018-02-28
- SevereDexamethasone Solution Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2014-01-22
- SeverePharmedium Recalls Dexamethasone Sodium Phosphate Infusions Due to Sterility Concerns
FDA (Drugs) · 2018-02-28
- SevereUS Compounding Recalls Dexamethasone Sodium Phosphate Vials Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- SevereFDA Recalls Injectable Solution Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereNew England Compounding Center Recalls Dexamethasone Sodium Phosphate Vials
FDA (Drugs) · 2013-01-09